$NOVO B (-0,48 %) is cutting 9,000 jobs worldwide about 11% of its workforce in a major restructuring to save $1.3 billion annually and refocus on growth in diabetes and obesity therapies. 5,000 layoffs are in Denmark. The move follows rising competition and a significant drop in profit forecasts for 2025.
